Ibogaine Safety — Risks, Screening & Protocols

Cardiac Screening Is Non-Negotiable

EKG screening to measure QTc interval is required before every ibogaine session. Patients with QTc above 450ms (men) or 470ms (women) are excluded. Continuous cardiac monitoring during the session is standard protocol.

Contraindications Must Be Screened

Absolute contraindications include cardiac arrhythmias, significant liver disease, active psychiatric conditions (bipolar disorder, schizophrenia), and concurrent use of certain medications including SSRIs and stimulants.

Setting Determines Safety

Ibogaine must be administered in a clinical setting with continuous monitoring, crash cart availability, and trained medical staff. Unsupervised or underground administration carries significant risk.

Trained Facilitators Save Lives

The vast majority of ibogaine-related adverse events occur in unsupervised settings or with inadequately screened patients. Proper training, screening, and monitoring dramatically reduce risk.

The Primary Safety Concern: Cardiac Risk

Ibogaine's primary safety concern is its effect on cardiac electrical activity. Ibogaine prolongs the QT interval — a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle. Prolonged QT interval increases the risk of a potentially fatal arrhythmia called Torsades de Pointes. This risk is manageable with proper screening and monitoring, but it cannot be ignored.

Standard protocol requires a 12-lead EKG before every ibogaine session. Patients with a corrected QT interval (QTc) above 450ms in men or 470ms in women are typically excluded from treatment. Patients with a personal or family history of cardiac arrhythmia, Long QT Syndrome, or sudden cardiac death are also excluded. During the session, continuous cardiac monitoring is maintained throughout the acute phase.

Drug Interactions and Contraindications

Several drug classes interact dangerously with ibogaine. SSRIs and SNRIs can cause serotonin syndrome when combined with ibogaine and must be tapered before treatment. Stimulants (cocaine, amphetamines) increase cardiac risk. Opioid agonists taken too close to the session can blunt ibogaine's effects. A comprehensive drug interaction screening is essential for every patient.

Psychiatric contraindications include active psychosis, bipolar disorder with recent manic episodes, and severe borderline personality disorder. Liver disease is a contraindication because ibogaine is metabolized hepatically — impaired liver function can lead to dangerously elevated ibogaine levels. Liver function panels (ALT, AST, bilirubin) are standard pre-screening.

How many people have died from ibogaine?

Ibogaine-related deaths are rare but documented — estimated at fewer than 30 worldwide in published literature. The vast majority occurred in unsupervised settings, with inadequate screening, or in patients with undetected cardiac conditions. Deaths at properly screened, medically supervised clinics are extremely rare.

Is ibogaine safe for everyone?

No. Ibogaine has significant contraindications including cardiac conditions, certain psychiatric diagnoses, liver disease, and drug interactions. Proper screening by a trained clinical facilitator is essential to identify who is and is not a safe candidate.

What training do ibogaine facilitators need?

Clinical facilitators need training in cardiac monitoring, EKG interpretation, medical screening protocols, dosing calculation, emergency response, and drug interaction assessment. Texas Ibogaine Institute's Tier 2 program covers all of these areas.

Can ibogaine be administered safely outside a clinic?

No. Ibogaine requires continuous cardiac monitoring, crash cart availability, and trained medical staff. Unsupervised or home administration is dangerous and has been responsible for the majority of ibogaine-related adverse events.